Published in Cancer Treat Rep on January 01, 1983
In vitro activities of furoquinoline and acridone alkaloids against Plasmodium falciparum. Antimicrob Agents Chemother (1994) 1.55
Protein Recognition in Drug-Induced DNA Alkylation: When the Moonlight Protein GAPDH Meets S23906-1/DNA Minor Groove Adducts. Int J Mol Sci (2015) 0.77
Anticancer Alkaloids from Trees: Development into Drugs. Pharmacogn Rev (2017) 0.75
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol (1997) 5.89
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol (1998) 3.64
Management of adult acute myelogenous leukaemia. Br Med J (1973) 3.33
Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res (1994) 3.20
Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol (1994) 2.94
Immunotherapy for acute myelogenous leukaemia. Br J Cancer (1973) 2.67
Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia. Br Med J (1970) 2.51
Lymphoid cellular responses in the blood after immunization in man. J Exp Med (1969) 2.25
Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. Br J Cancer (1997) 2.18
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer (1987) 1.97
Six cases of gamma-D myelomatosis. Lancet (1966) 1.92
The recognition of psychiatric morbidity on a medical oncology ward. J Psychosom Res (1989) 1.84
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer (1999) 1.80
Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold. BMJ (1999) 1.77
Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood (2001) 1.75
The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol (1988) 1.73
Combination chemotherapy in generalized Hodgkin's disease. Br Med J (1970) 1.67
The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer (1989) 1.65
Psychological problems associated with diagnosis and treatment of lymphomas. I: Retrospective study. Br Med J (Clin Res Ed) (1987) 1.60
p53 germline mutations in Li-Fraumeni syndrome. Lancet (1991) 1.58
Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood (1993) 1.56
Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet (1984) 1.56
Reactive lymphoid cells ('Immunoblasts') in autoimmune and haematological disorders. Clin Exp Immunol (1975) 1.52
MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J (1978) 1.46
Identification and characterization of a novel human vanilloid receptor-like protein, VRL-2. Physiol Genomics (2001) 1.46
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood (1992) 1.45
A phase II study of human rDNA alpha-2 interferon in patients with low grade non-Hodgkin's lymphoma. Cancer Chemother Pharmacol (1986) 1.43
Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. Br J Cancer (1977) 1.43
Relative activities of linear and cyclic electron flows during chloroplast CO2-fixation. Biochim Biophys Acta (1980) 1.42
L-asparaginase in treatment of acute leukaemia and lymphosarcoma. Br Med J (1970) 1.39
Tumour lysis syndrome, case report and review of the literature. Ann Oncol (1996) 1.39
The role of postoperative alkylating agent therapy in early-stage epithelial ovarian cancer. Br J Obstet Gynaecol (1989) 1.38
A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer (1993) 1.38
Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet (1983) 1.35
Computed tomography of abdomen in staging and clinical management of lymphoma. Br Med J (1978) 1.34
Combination chemotherapy in advanced and recurrent Hodgkin's disease. Natl Cancer Inst Monogr (1973) 1.33
Factors influencing prognosis in adults with acute myelogenous leukaemia. Br J Cancer (1975) 1.29
Non-secretory multiple myeloma: a report of 13 cases with a review of the literature. Hematol Oncol (1987) 1.29
The involvement of ferredoxin-NADP+ reductase in cyclic electron transport in chloroplasts. Biochim Biophys Acta (1981) 1.29
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer (1998) 1.27
Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer (2000) 1.26
The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male. Cancer (1982) 1.26
Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. Br Med J (1978) 1.25
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial. J Clin Oncol (1990) 1.25
Lymphoid cells in Hodgkin's disease. Nature (1967) 1.23
Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ (1997) 1.20
Active immunotherapy in treatment of acute leukaemia. Br Med J (1969) 1.19
A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer (1995) 1.19
Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma. Br J Cancer (1977) 1.18
Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Lancet (1984) 1.18
Human lymphocyte traffic assessed by indium-111 oxine labelling: clinical observations. Clin Exp Immunol (1981) 1.16
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol (1998) 1.15
Partial characterization of cyclic electron transport in intact chloroplasts. Arch Biochem Biophys (1980) 1.15
A method for following human lymphocyte traffic using indium-111 oxine labelling. Clin Exp Immunol (1981) 1.15
Abdomino-pelvic computed tomography in the management of ovarian carcinoma. Radiology (1983) 1.15
In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer (1988) 1.14
PCR-ELISA for the early diagnosis of invasive pulmonary aspergillus infection in neutropenic patients. J Clin Pathol (1998) 1.13
Urinary retention after total hip replacement. A prospective study. J Bone Joint Surg Br (1987) 1.12
Relationship between the pretreatment proliferative activity of marrow blast cells and prognosis of acute lymphoblastic leukaemia of childhood. Br J Cancer (1980) 1.11
Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol (2000) 1.10
Computed tomography (CT) in the staging of patients with Hodgkin's Disease: a report on 136 patients. Clin Radiol (1980) 1.10
Abnormal peripheral blood lymphocytes and bone marrow infiltration in non-Hodgkin's lymphoma. Br J Haematol (1979) 1.09
Viridans streptococcal bacteraemia in patients with haematological and solid malignancies. Eur J Cancer (1991) 1.08
Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood (1993) 1.08
Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol (1987) 1.07
Prognostic significance of osteopenia and immunoparesis at presentation in patients with solitary myeloma of bone. Eur J Cancer (1990) 1.06
Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. Antimicrob Agents Chemother (1989) 1.06
Combination chemotherapy for acute lymphoblastic leukaemia in adults. Br Med J (1978) 1.06
Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant (1999) 1.05
A study of gastro-intestinal lymphoma. Clin Oncol (1979) 1.05
Evaluation of serum beta 2-microglobulin as a prognostic indicator in myelomatosis. Br J Cancer (1983) 1.05
Early central nervous system involvement in adults with acute non-myelogenous leukaemia. Br J Cancer (1977) 1.05
Intensive investigation in management of Hodgkin's disease. Br Med J (1976) 1.04
VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer (1995) 1.04
Electron transport pathways in spinach chloroplasts. Reduction of the primary acceptor of photosystem II by reduced nicotinamide adenine dinucleotide phosphate in the dark. Biochim Biophys Acta (1979) 1.03
Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres. Br J Cancer (1988) 1.02
Epidemiology of an outbreak due to glycopeptide-resistant Enterococcus faecium on a leukaemia unit. J Hosp Infect (1996) 1.02
L-asparaginase and human malignant disease. Nature (1971) 1.01
Factors influencing microculture in leukaemia cells. Nature (1974) 1.01
Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro. Cancer Immunol Immunother (1994) 1.00
Hypothesis: persistent expression of fetal phenotypic characteristics by fibroblasts is associated with an increased susceptibility to neoplastic disease. Exp Cell Biol (1987) 1.00
The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer (1983) 1.00
Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study. Br Med J (Clin Res Ed) (1987) 0.99
Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen. J Clin Oncol (1995) 0.98
Adriamycin in the treatment of acute leukaemia. Br Med J (1972) 0.98
Central venous catheter placement: extending the role of the nurse. J R Coll Physicians Lond (1998) 0.98